Molecular basis of agonism and antagonism in the oestrogen receptor
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Oestrogens are involved in the growth, development and homeostasis of a number of tissues. The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER). Hormone binding to the ligand-binding domain (LBD) of the ER initiates a series of molecular events culminating in the activation or repression of target genes. Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery. Here we report the crystal structures of the LBD of ER in complex with the endogenous oestrogen, 17beta-oestradiol, and the selective antagonist raloxifene, at resolutions of 3.1 and 2.6 A, respectively. The structures provide a molecular basis for the distinctive pharmacophore of the ER and its catholic binding properties. Agonist and antagonist bind at the same site within the core of the LBD but demonstrate different binding modes. In addition, each class of ligand induces a distinct conformation in the transactivation domain of the LBD, providing structural evidence of the mechanism of antagonism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We previously found that the full-length ERα dimer forms a symmetric tail-to-tail dimer in the ERα/SRC-3/p300 complex (Yi et al., 2015), consistent with the nature of palindromic DNA binding sequence, symmetric X-ray crystal structures of the ERα LBD (Brzozowski et al., 1997) and DBD dimers (Schwabe et al., 1993).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Brzozowski et al., 1997
In the citing paper
“the AR LBD interacts weakly with LXXLL motif-containing coactivators, such as SRCs, (Brzozowski et al., 1997; Dubbink et al., 2006; He et al., 2004; He et al., 1999; Matias et al., 2000; Nadal et al., 2017).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Brzozowski et al., 1997
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475 · cited 1×
“Data were integrated and reduced using the programs DENZO and SCALEPAC”
MethodPROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions
Wallace, A. C., Laskowski, R. A., & Thornton, J. M. (1995) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/8.2.127 · Cited by 5,690
MOLECULAR MECHANISMS OF ACTION OF STEROID/THYROID RECEPTOR SUPERFAMILY MEMBERS
Tsai, M.-J., & O'Malley, B. W. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.002315 · Cited by 2,932 · cited 1×
“The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER”
BackgroundThe estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer
Kumar, V., & Chambon, P. (1988) · Cell · doi:10.1016/0092-8674(88)90017-7 · Cited by 1,220 · cited 1×
“The ER LBDs are arranged as non-crystallographic dimers within both the E 2 and RAL complex crystals in a manner consistent with both the oligomeric state of liganded ER in solutio”
BackgroundCrystal structure of the ligand-binding domain of the human nuclear receptor RXR-α
Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/375377a0 · Cited by 1,177 · cited 1×
“The overall architecture of the ER LBD (helices H3–H12) is similar to that seen in the crystal structures of other nuclear receptor LBD”
BackgroundCrystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid
Renaud, J.-P., Rochel, N., Ruff, M., Vivat, V., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/378681a0 · Cited by 1,097 · cited 1×
“The overall architecture of the ER LBD (helices H3–H12) is similar to that seen in the crystal structures of other nuclear receptor LBD”
BackgroundA canonical structure for the ligand-binding domain of nuclear receptors
Wurtz, J.-M., Bourguet, W., Renaud, J.-P., Vivat, V., Chambon, P., Moras, D., & Gronemeyer, H. (1996) · Nature Structural Biology · doi:10.1038/nsb0196-87 · Cited by 985 · cited 1×
“, and emphasizes the universal nature of this fold within this receptor superfamil”
Background
Cited by
Items 501–600 of 1,012
Nawaz, Z., & O’Malley, B. W. (2004) · Molecular Endocrinology · doi:10.1210/me.2003-0388 · Cited by 132
The ligand binding profiles of estrogen receptors α and β are species dependent
Harris, H. A., Bapat, A. R., Gonder, D. S., & Frail, D. E. (2002) · Steroids · doi:10.1016/s0039-128x(01)00194-5 · Cited by 150
Design, Synthesis, and Preclinical Characterization of Novel, Highly Selective Indole Estrogens
Miller, C. P., Collini, M. D., Tran, B. D., Harris, H. A., Kharode, Y. P., Marzolf, J. T., Moran, R. A., Henderson, R. A., Bender, R. H. W., Unwalla, R. J., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010086m · Cited by 150
Qin, Z., Kastrati, I., Chandrasena, R. E. P., Liu, H., Yao, P., Petukhov, P. A., Bolton, J. L., & Thatcher, G. R. J. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070079j · Cited by 150
Gangloff, M., Ruff, M., Eiler, S., Duclaud, S., Wurtz, J., & Moras, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009870200 · Cited by 150
Fujita-Sato, S., Ito, S., Isobe, T., Ohyama, T., Wakabayashi, K., Morishita, K., Ando, O., & Isono, F. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.254003 · Cited by 137
Structure and physiological functions of the human peroxisome proliferator-activated receptor γ
Zieleniak, A., Wójcik, M., & Woźniak, L. A. (2008) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-008-0037-y · Cited by 149
“The conformation of helix 12 is critical for transcriptional activation since significant differences have been observed in the location of this helix for agonist and antagonist-bound forms of the estrogen receptor [18].”
BackgroundMonroe, D. G., Secreto, F. J., Subramaniam, M., Getz, B. J., Khosla, S., & Spelsberg, T. C. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0381 · Cited by 154
Hong, H., Tong, W., Fang, H., Shi, L., Xie, Q., Wu, J., Perkins, R., Walker, J. D., Branham, W., & Sheehan, D. M. (2002) · Environmental Health Perspectives · doi:10.1289/ehp.0211029 · Cited by 141
Determinants of CoRNR-Dependent Repression Complex Assembly on Nuclear Hormone Receptors
Hu, X., Li, Y., & Lazar, M. A. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1747-1758.2001 · Cited by 132
“There is flexibility in the sequences that each docking site can accommodate, since in the antagonist-bound NHR crystal structure, H12 binds in orientation A to prevent interaction with coactivators (3, 37).”
BackgroundHydroxysteroid dehydrogenases and pre-receptor regulation of steroid hormone action
Penning, T. M. (2003) · Human Reproduction Update · doi:10.1093/humupd/dmg022 · Cited by 140
“This view has been supplanted by the concept that ligands alter the conformation of the receptor (Brzozowksi et al., 1997; Wijayaratne et al., 1999) to recruit tissue-speci®c co- activators (CA; e.g., SRC-1/NcoA-1) and co-repressors (CR; e.g. NcoR, SMRT) leading to a graded response (Klinge,…”
A structural view of nuclear hormone receptor: endocrine disruptor interactions
le Maire, A., Bourguet, W., & Balaguer, P. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0249-2 · Cited by 149
“In the ERs, the hormone binding pockets are lined with 20 mostly hydrophobic residues that interact with the steroid scaffold [46, 47].”
Maruyama, K., Endoh, H., Sasaki-Iwaoka, H., Kanou, H., Shimaya, E., Hashimoto, S., Kato, S., & Kawashima, H. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8590 · Cited by 154
The ovarian phenotype of the aromatase knockout (ArKO) mouse
Britt, K. L., Drummond, A. E., Dyson, M., Wreford, N. G., Jones, M. E. E., Simpson, E. R., & Findlay, J. K. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00158-3 · Cited by 148
Koide, A., Abbatiello, S., Rothgery, L., & Koide, S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.032665299 · Cited by 134
Raloxifene: A Selective Estrogen Receptor Modulator (SERM) with Multiple Target System Effects
Muchmore, D. B. (2000) · The Oncologist · doi:10.1634/theoncologist.5-5-388 · Cited by 134
“Although the mechanism by which SERMs exhibit their complex profiles is not completely understood, characterization of the x-ray crystallographic structure of the ER, when bound to raloxifene, provided insight into this receptor/ligand interaction [ 5 ].”
BackgroundAntiestrogens – Tamoxifen, SERMs and Beyond
Dhingra, K. (1999) · Investigational New Drugs · doi:10.1023/a:1006348907994 · Cited by 148
“Crystal structure of the LBD of ER bound to its natural ligand, estradiol, or a synthetic ligand, raloxifene, reveals that both of these molecules bind to the same site in the LBD with the hydroxyl group of the benzothiophene moiety of raloxifene mimicking the A-ring phenolic hydroxyl of estradiol and making hydrogen…”
BackgroundStructural mechanism for signal transduction in RXR nuclear receptor heterodimers
Kojetin, D. J., Matta-Camacho, E., Hughes, T. S., Srinivasan, S., Nwachukwu, J. C., Cavett, V., Nowak, J., Chalmers, M. J., Marciano, D. P., Kamenecka, T. M., et al. (2015) · Nature Communications · doi:10.1038/ncomms9013 · Cited by 129
“Some NR antagonists, such as tamoxifen or RU486, contain a pendent side group that physically relocates helix 12 out of the active conformation thus blocking coactivator recruitment 15,19,20 .”
Differential Recruitment of the Mammalian Mediator Subunit TRAP220 by Estrogen Receptors ERα and ERβ
Wärnmark, A., Almlöf, T., Leers, J., Gustafsson, J.-Å., & Treuter, E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011651200 · Cited by 129
Self-citationSocorro, S., Power, D. M., Olsson, P., & Canário, A. V. M. (2000) · Journal of Endocrinology · doi:10.1677/joe.0.1660293 · Cited by 149
“1992) is completely conserved in both clones (Figs 1 and 2); in addition, amino acids in the LBD shown in hER to be involved in E2 binding (Brzozowski et al. 1997) are also conserved in sea bream ERs (Figs 1 and 2).”
BackgroundInfluentialPutative functional characteristics of human estrogen receptor-beta isoforms
Peng, B., Lu, B., Leygue, E., & Murphy, L. C. (2003) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0300013 · Cited by 147
Körner, W., Spengler, P., Bolz, U., Schuller, W., Hanf, V., & Metzger, J. W. (2001) · Environmental Toxicology and Chemistry · doi:10.1002/etc.5620201002 · Cited by 147
“This surprising structural diversity of xeno- and phytoestrogens has been confirmed by elucidation of the crystal structure of the ligand-binding domain of the human estrogen receptor alpha (hERa) [30].”
BackgroundResveratrol modulates the inflammatory response via an estrogen receptor-signal integration network
Nwachukwu, J. C., Srinivasan, S., Bruno, N. E., Parent, A. A., Hughes, T. S., Pollock, J. A., Gjyshi, O., Cavett, V., Nowak, J., Garcia-Ordonez, R. D., et al. (2014) · eLife · doi:10.7554/elife.02057 · Cited by 137
The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer
Jordan, V. C. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0448 · Cited by 145
“X-ray crystallography (Brzozowski et al. 1997, Shiau et al. 1998) of the ligand-binding domain of the ER liganded with a class I estrogen (i.e., E2 or DES) or with a nonsteroidal antiestrogen (i.e., 4-OHT or raloxifene) provides precise structural data for the extremes of estrogen and antiestrogen…”
Simigdala, N., Gao, Q., Pancholi, S., Røberg‐Larsen, H., Zvelebil, M., Ribas, R., Folkerd, E. J., Thompson, A., Bhamra, A., Dowsett, M., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0713-5 · Cited by 145
“Furthermore, using the crystal structure of the Activation Function 2 (AF2) [49] domain of ER, which incorporates the LBD, both 25-HC and 27-HC were successfully docked and were superimposed on E2, supporting this hypothesis (Fig.”
Estrogen receptors in pain modulation: cellular signaling
Chen, Q., Zhang, W., Sadana, N., & Chen, X. (2021) · Biology of Sex Differences · doi:10.1186/s13293-021-00364-5 · Cited by 145
“The two classic nuclear ERs share a high degree of homology in their modular structure, including the DNA-binding domain and ligand-binding domain [60].”
BackgroundWang, L., Zuercher, W. J., Consler, T. G., Lambert, M. H., Miller, A. B., Orband-Miller, L. A., McKee, D. D., Willson, T. M., & Nolte, R. T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608410200 · Cited by 136
Wittmann, B. M., Sherk, A., & McDonnell, D. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1590 · Cited by 126
Androgen-Induced Regrowth in the Castrated Rat Ventral Prostate: Role of 5α-Reductase1
Wright, A. S., Douglas, R. C., Thomas, L. N., Lazier, C. B., & Rittmaster, R. S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7039 · Cited by 121
“The influence of the ligand on nuclear receptor structure and action is beginning to be understood (28).”
BackgroundMeyers, M. J., Sun, J., Carlson, K. E., Katzenellenbogen, B. S., & Katzenellenbogen, J. A. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990101b · Cited by 137
Molecular and pharmacological aspects of antiestrogen resistance
Clarke, R. C., Skaar, T. C., Bouker, K. B., Davis, N., Lee, Y. R., Welch, J. N., & Leonessa, F. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00193-x · Cited by 145
Nonnuclear Actions of Estrogen
Ho, K. J., & Liao, J. K. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000041200.85946.4a · Cited by 127
Greschik, H., Flaig, R., Renaud, J.-P., & Moras, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402195200 · Cited by 129
“In most documented cases AF2 antagonism is based on sterical interference between a bulky ligand extension protruding from the LBP and H12 in the agonist position, as exemplified by the ERα LBD bound to RAL or 4-OHT (28, 29) or the ERβ LBD complexed with ICI 164,384 (ICI) (30).”
BackgroundInfluentialIn Vitro and in Vivo Antiestrogenic Effects of Polycyclic Musks in Zebrafish
Schreurs, R. H. M. M., Legler, J., Artola‐Garicano, E., Sinnige, T. L., Lanser, P. H., Seinen, W., & van der Burg, B. (2003) · Environmental Science & Technology · doi:10.1021/es034648y · Cited by 143
Coupling of receptor conformation and ligand orientation determine graded activity
Bruning, J. B., Parent, A. A., Gil, G., Zhao, M., Nowak, J., Pace, M. C., Smith, C. L., Afonine, P. V., Adams, P. D., Katzenellenbogen, J. A., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.451 · Cited by 142
Fukuzawa, K., Kitaura, K., Uebayasi, M., Nakata, K., Kaminuma, T., & Nakano, T. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20130 · Cited by 142
Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension
Fagart, J., Huyet, J., Pinon, G. M., Rochel, M., Mayer, C., & Rafestin-Oblin, M. E. (2005) · Nature Structural & Molecular Biology · doi:10.1038/nsmb939 · Cited by 142
O'Regan, R. M., & Jordan, V. C. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00711-8 · Cited by 142
Chan, H. J., Petrossian, K., & Chen, S. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.07.018 · Cited by 143
“and endometrium [102], or in breast cancer cells that have become resistant to TAM, the drug acts as a partial agonist of ER and may recruit coregulatory proteins to modulate some estrogen responsive genes [103-105].”
BackgroundOwens, J. W., & Ashby, J. (2002) · Critical Reviews in Toxicology · doi:10.1080/20024091064291 · Cited by 124
“In support of this model, HO-TAM appears to disrupt the binding of coactivation factors to ERα by displacing helix 12 to an inactive position in the crystal structure of the ligand-receptor complex (Brzozowski et al., 1997).”
BackgroundAR and ER Interaction with a p21-Activated Kinase (PAK6)
Lee, S. R. (2002) · Molecular Endocrinology · doi:10.1210/me.16.1.85 · Cited by 134
Alen, P., Claessens, F., Schoenmakers, E., Swinnen, J. V., Verhoeven, G., Rombauts, W., & Peeters, B. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.1.0214 · Cited by 116
“The crystal structures of the LBDs of unliganded human retinoid X receptor-a (hRXRa) (8), of ligand-bound human retinoic acid receptor-g (hRARg) (9), thyroid hormone receptor (TR) (10), and progesterone receptor (PR) (11) and of agonist and antagonist-bound estrogen receptor (ER) (12) revealed a common overall layered…”
BackgroundRosati, R. L., Jardine, P. D. S., Cameron, K. O., Thompson, D. D., Ke, H. Z., Toler, S. M., Brown, T. A., Pan, L. C., Ebbinghaus, C. F., Reinhold, A. R., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980048b · Cited by 141
Progress and challenges of selective Farnesoid X Receptor modulation
Massafra, V., Pellicciari, R., Gioiello, A., & van Mil, S. W. C. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.009 · Cited by 143
Marciano, D. P., Chang, M. R., Corzo, C. A., Goswami, D., Lam, V. Q., Pascal, B. D., & Griffin, P. R. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.12.009 · Cited by 140
“SR1664 was derived from the potent partial agonist SPPARM GSK538 (Lamotte et al., 2010) and was designed to actively antagonize the receptor through an AF2 clash to ablate classical agonism as previously described for the estrogen receptor (Brzozowski et al., 1997; Shiau et al., 1998).”
MethodLessons learnt from structural studies of the oestrogen receptor
Pike, A. C. W. (2006) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2005.09.002 · Cited by 140
Self-citationRole of Cadmium in the Regulation of AR Gene Expression and Activity
Martin, M. B., Voeller, H. J., Gelmann, E. P., Lü, J., Stoica, E.-G., Hebert, E. J., Reiter, R., Singh, B., Danielsen, M., Pentecost, E., et al. (2002) · Endocrinology · doi:10.1210/endo.143.1.8581 · Cited by 140
“They are composed of up to 12 -helices (H1-H12), folded into a three-layered antiparallel helical sandwich (23, 25, 82).”
BackgroundLevenson, A. S., & Jordan, V. C. (1998) · PubMed · Cited by 140
Seo, H.-S., DeNardo, D. G., Jacquot, Y., Laïos, I., Vidal, D. S., Zambrana, C. R., Leclercq, G., & Brown, P. H. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9191-2 · Cited by 139
“The hERa/E2 X-ray structure (PDB code: 1ERE, complex A) [ 31 ] was used as a search model.”
BackgroundMethodInfluentialRogerson, F. M., & Fuller, P. J. (2000) · Steroids · doi:10.1016/s0039-128x(99)00087-2 · Cited by 115
Allosteric Modulation of Estrogen Receptor Conformation by Different Estrogen Response Elements
Wood, J. R. (2001) · Molecular Endocrinology · doi:10.1210/me.15.7.1114 · Cited by 116
The importance of ERβ signalling in the ovary
Drummond, A. E., & Fuller, P. J. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0379 · Cited by 141
Krolick, K. N., Zhu, Q., & Shi, H. (2018) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2018.07.008 · Cited by 138
A Series of Unconjugated Ferrocenyl Phenols: Prospects as Anticancer Agents
Hillard, E. A., Vessières, A., Bideau, F. L., Plażuk, D., Spera, D., Huché, M., & Jaouen, G. (2006) · ChemMedChem · doi:10.1002/cmdc.200500035 · Cited by 138
Grese, T. A., Pennington, L. D., Sluka, J. P., Adrian, M. D., Cole, H. W., Fuson, T. R., Magee, D. E., Phillips, D. L., Rowley, E. R., Shetler, P. K., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970688z · Cited by 138
Stossi, F., Likhite, V. S., Katzenellenbogen, J. A., & Katzenellenbogen, B. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513405200 · Cited by 118
Vottero, A. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.6.2658 · Cited by 126
Tria, G. S., Abrams, T., Baird, J., Burks, H. E., Firestone, B., Gaither, L. A., Hamann, L. G., He, G., Kirby, C. A., Kim, S., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01682 · Cited by 128
Improving Structure-Based Virtual Screening by Multivariate Analysis of Scoring Data
Jacobsson, M., Lidén, P., Stjernschantz, E., Boström, H., & Norinder, U. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030896t · Cited by 126
Wang, Z., Zhang, X., Wang, H., Li, Q., & Lou, Y. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.12.059 · Cited by 137
Differential Response of Estrogen Receptor Subtypes to 1,3-Diarylindene and 2,3-Diarylindene Ligands
Clegg, N. J., Paruthiyil, S., Leitman, D. C., & Scanlan, T. S. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050226i · Cited by 136
Nichols, M., Rientjes, J. M. J., & Stewart, A. F. (1998) · The EMBO Journal · doi:10.1093/emboj/17.3.765 · Cited by 137
“The helix 10 inversion mutations identified here occur along the dimerization interface, though the exact position of 508 and other helix 10 residues was not presented in the crystal structures (note: helix 10 and 11 are contiguous in the ER LBD and are simply refered to as helix 11 in the recent structure; Brzozowski…”
BackgroundInfluentialMULTIPROTEIN-DNA COMPLEXES IN TRANSCRIPTIONAL REGULATION
Wolberger, C. (1999) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.28.1.29 · Cited by 119
Gee, A. C. (1999) · Molecular Endocrinology · doi:10.1210/me.13.11.1912 · Cited by 129
“The first x-ray crystal structures of the ER complexed with the agonist estradiol and the mixed antagonist raloxifene were already suggestive of the manner in which the NR box sequences in steroid receptor coactivators would interact with ER and how this might be regulated by the ligand (17).”
Ligands Specify Coactivator Nuclear Receptor (NR) Box Affinity for Estrogen Receptor Subtypes
Bramlett, K. S. (2001) · Molecular Endocrinology · doi:10.1210/me.15.6.909 · Cited by 119
“Binding of the SERMs results in unique positioning of H12 so that this helix actually obstructs the groove by mimicking the LXXLL domain with the sequence LXXML from H12 of the LBD, which is conserved in all NRs (34, 45).”
BackgroundInfluentialSimoncini, T., Genazzani, A. R., & Liao, J. K. (2002) · Circulation · doi:10.1161/hc1102.105267 · Cited by 125
Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer
Fabian, C. J., & Kimler, B. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.005 · Cited by 118
Molecular Cloning of an Estrogen Receptor β Subtype from the Goldfish,Carassius auratus
Tchoudakova, A., Pathak, S., & Callard, G. V. (1999) · General and Comparative Endocrinology · doi:10.1006/gcen.1998.7217 · Cited by 136
Allosteric Modulators of Steroid Hormone Receptors: Structural Dynamics and Gene Regulation
Kumar, R., & McEwan, I. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1033 · Cited by 135
Molecular mechanism of a cross‐talk between oestrogen and growth factor signalling pathways
Kato, S., Masuhiro, Y., Watanabe, M., Kobayashi, Y., Takeyama, K., Endoh, H., & Yanagisawa, J. (2000) · Genes to Cells · doi:10.1046/j.1365-2443.2000.00354.x · Cited by 137
Kojetin, D. J., & Burris, T. P. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.079285 · Cited by 137
“It has been observed generally that agonist ligands position helix 12 to cap the ligand-binding site, leaving the AF-2 surface exposed for coregulator binding (Brzozowski et al., 1997).”
BackgroundEvolution of a New Function by Degenerative Mutation in Cephalochordate Steroid Receptors
Bridgham, J. T., Brown, J. E., Rodríguez-Marí, A., Catchen, J. M., & Thornton, J. W. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000191 · Cited by 122
The bioavailability of non-nutrient plant factors: dietary flavonoids and phyto-oestrogens
Wiseman, H. (1999) · Proceedings of The Nutrition Society · doi:10.1079/pns19990019 · Cited by 135
“The molecular basis of agonism and antagonism at the oestrogen receptor has only recently been elucidated (Brzozowski et al. 1997).”
BackgroundThyroid Hormone Receptor Coactivators and Corepressors
KOENIG, R. J. (1998) · Thyroid · doi:10.1089/thy.1998.8.703 · Cited by 126
“Also of interest is the crys¬ tal structure of the estrogen receptor LBD bound to 17/3-estradiol or the selective receptor antagonist raloxifene (28).”
Sapone, A., Peters, J. M., Sakai, S., Tomita, S., Papiha, S. S., Dai, R., Friedman, F. K., & Gonzalez, F. J. (2000) · Pharmacogenetics · doi:10.1097/00008571-200006000-00006 · Cited by 130
Specific Recognition of Androgens by Their Nuclear Receptor
Poujol, N., Wurtz, J.-M., Tahiri, B., Lumbroso, S., Nicolas, J.-C., Moras, D., & Sultan, C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001999200 · Cited by 122
Barry, N. P. E., & Sadler, P. J. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15300a · Cited by 134
Yi, P., Driscoll, M. D., Huang, J., Bhagat, S., Hilf, R., Bambara, R. A., & Muyan, M. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.4.0810 · Cited by 97
Minireview: Not Picking Pockets: Nuclear Receptor Alternate-Site Modulators (NRAMs)
Moore, T. W., Mayne, C. G., & Katzenellenbogen, J. A. (2010) · Molecular Endocrinology · doi:10.1210/me.2009-0362 · Cited by 123
“It is curious, however, to find a second molecule of 4-OH-TAM bound in a groove that, at least in ER , is normally occluded by helix-12 in ER complexes with SERMs (63, 76).”
Okuhira, K., Demizu, Y., Hattori, T., Ohoka, N., Shibata, N., Nishimaki‐Mogami, T., Okuda, H., Kurihara, M., & Naito, M. (2013) · Cancer Science · doi:10.1111/cas.12272 · Cited by 128
Current Status of Vitamin D Signaling and Its Therapeutic Applications
Carlberg, C., & Molnár, F. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612799436623 · Cited by 133
“Endocrine members of the nuclear receptor superfamily, such as ERs [34], bind with high affinity to a specific ligand and have a small LBP.”
BackgroundHydrogen/deuterium‐exchange (H/D‐Ex) of PPARγ LBD in the presence of various modulators
Hamuro, Y., Coales, S. J., Morrow, J. A., Molnar, K. S., Tuske, S. J., Southern, M. R., & Griffin, P. R. (2006) · Protein Science · doi:10.1110/ps.062103006 · Cited by 135
“Many biochemical and biophysical studies on this class of receptors suggest that agonists or antagonists binding induce conformational changes in the ligand binding domain (LBD) (Brzozowski et al. 1997; Pike et al. 1999; Johnson et al. 2000; Berger et al. 2003; Kallenberger et al. 2003).”
BackgroundBohl, C. E., Wu, Z. R., Miller, D. D., Bell, C. E., & Dalton, J. T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611711200 · Cited by 133
Vivacqua, A., Recchia, A. G., Fasanella, G., Gabriele, S., Carpino, A., Rago, V., Gioia, M. L. D., Leggio, A., Bonofiglio, D., Liguori, A., et al. (2003) · Endocrine · doi:10.1385/endo:22:3:275 · Cited by 133
Pure oestrogen antagonists for the treatment of advanced breast cancer
Howell, A. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.00846 · Cited by 114
“Ligand-specific conformational changes in the ER strongly influence the protein:protein interactions in the transcriptional complex, leading to differences in gene transcription and activation for ER-binding ligands (Brzozowski et al. 1997, Shiau et al. 1998).”
BackgroundX‐ray structure of the orphan nuclear receptor RORβ ligand‐binding domain in the active conformation
Stehlin, C., Wurtz, J., Steinmetz, A. C. U., Greiner, E. F., Schüle, R., Moras, D., & Renaud, J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.21.5822 · Cited by 133
Zwart, W. T., Griekspoor, A., Berno, V., Lakeman, K. A. M., Jalink, K., Mancini, M. A., Neefjes, J., & Michalides, R. J. A. M. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601791 · Cited by 134
“Antagonists of ERa act by altering the orientation of the C-terminally located a-helix 12 of the ligand binding domain (LBD) of ER (Brzozowski et al, 1997).”
BackgroundMolecular Switch in the Glucocorticoid Receptor: Active and Passive Antagonist Conformations
Schoch, G., D’Arcy, B., Stihle, M., Burger, D., Bär, D., Benz, J., Thoma, R., & Ruf, A. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.11.011 · Cited by 132
“Throughout this report, helix nomenclature from the original estrogen receptor structures will be used.(26) 571 Molecular Switch in the Glucocorticoid Receptor”
MethodStructure of the Murine Constitutive Androstane Receptor Complexed to Androstenol
Li, S., Vincent, J. G., Brunzelle, J. S., Dussault, I., Lin, M., Ianculescu, I., Sherman, M. A., FORMAN, B. M., & Fernandez, E. J. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.11.037 · Cited by 132
“This backbone Gln245-Glu339 interaction is likely to be significant, because it is conserved in many other receptors including ERα (His) (Brzozowski et al., 1997), LXRα (Gln) (Svensson et al.”
BackgroundInfluentialEstrogen receptor agonists for attenuation of neuroinflammation and neurodegeneration
Chakrabarti, M., Haque, A., Banik, N. L., Nagarkatti, P. S., Nagarkatti, M., & Ray, S. K. (2014) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2014.09.004 · Cited by 131
Runx2 Integrates Estrogen Activity in Osteoblasts
McCarthy, T. L., Chang, W.-Z., Liu, Y., & Centrella, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306531200 · Cited by 116
Wang, Y., Chirgadze, N. Y., Briggs, S. L., Khan, S., Jensen, E. V., & Burris, T. P. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510596103 · Cited by 112
Selective Estrogen Receptor Modulators in the Ruthenocene Series. Synthesis and Biological Behavior
Pigeon, P., Top, S., Vessières, A., Huché, M., Hillard, E. A., Salomon, E., & Jaouen, G. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049268h · Cited by 131
The role of estrogen receptor α in the regulation of bone and growth plate cartilage
Börjesson, A., Lagerquist, M. K., Windahl, S. H., & Ohlsson, C. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1317-1 · Cited by 131
Sornalingam, K., McDonagh, A. M., & Zhou, J. L. (2016) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2016.01.086 · Cited by 130
“In summary, estrogenic activity has been attributed to the interaction of the phenolic moiety with estrogen receptors (Brzozowski et al., 1997; Mboula et al., 2015).”
BackgroundBinding Characteristics of Dialkyl Phthalates for the Estrogen Receptor
Nakai, M., Tabira, Y., Asai, D., Yakabe, Y., Shimyozu, T., Noguchi, M., Takatsuki, M., & Shimohigashi, Y. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9928 · Cited by 130
McDonnell, D. P., Connor, C. E., Wijayaratne, A., Chang, C.-Y., & Norris, J. D. (2002) · Recent Progress in Hormone Research · doi:10.1210/rp.57.1.295 · Cited by 130
“As with the protease digestion experiments, crystallography has not yet been able to provide an obvious explanation for the observed functional differences between tamoxifen and other SERMs like raloxifene (Brzozowski et al., 1997; Pike et al., 1999).”
InfluentialFrom Androgen Receptor to the General Transcription Factor TFIIH
Lee, D. K., Duan, H. O., & Chang, C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.13.9308 · Cited by 116
Analysis of protein dimerization and ligand binding of orphan receptor HNF4α
Bogan, A. A., Dallas-Yang, Q., Ruse, M. D., Maeda, Y., Jiang, G., Nepomuceno, L., Scanlan, T. S., Cohen, F. E., & Sladek, F. M. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4099 · Cited by 129
Selective estrogen receptor modulators in clinical practice: a safety overview
Ellis, A., Hendrick, V. M., Williams, R., & Komm, B. S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1014799 · Cited by 129
“2 Raloxifene Crystal structures show that raloxifene induces an alternative, transcriptionally inactive ER ligand binding domain conformation, resulting in a loss of ER-mediated pharmacological effects in certain tissues compared with estradiol [12].”
Background
Metadata
- Authors
- Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M.
- Affiliations
- University of York (GB)
- Karo Pharma (Sweden) (SE)
- University of Chicago (US)
- Corresponding author
- Hubbard, Roderick E.
- ORCID
- Venue
- Nature
- Published
- 1997-10
- Volume
- 389
- Issue
- 6652
- Pages
- 753-758
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2101738855
- Cited by
- 3,355
- References
- 29
- Citations by year
- 2026: 49 · 2025: 55 · 2024: 55 · 2023: 61 · 2022: 62 · 2021: 91 · 2020: 55 · 2019: 75 · 2018: 73 · 2017: 65 · 2016: 72 · 2015: 74 · 2014: 94 · 2013: 105 · 2012: 104
- FWCI
- 94.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Keywords
- oestrogen receptor, ligand-binding domain, estradiol, raloxifene, selective estrogen receptor modulators, crystal structure, transcriptional regulation
- MeSH terms
- Binding Sites, Estradiol, Estrogen Antagonists, Humans, Models, Molecular, Piperidines, Protein Conformation, Receptors, Estrogen, Crystallography, X-Ray, Raloxifene Hydrochloride
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.